Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arch Therapeutics Inc (ARTH)

Arch Therapeutics Inc (ARTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing

Uplisting is the Next Significant Step...

ARTH : 0.1608 (-19.60%)
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarter...

ARTH : 0.1608 (-19.60%)
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring

World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound System...

ARTH : 0.1608 (-19.60%)
Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring

Additional data covered a variety of specialties, including vascular surgery, plastic surgery, general surgery, and podiatry, to further support clinical...

ARTH : 0.1608 (-19.60%)
Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring

Additional case studies and key opinion leader discussion continues to support the broad potential of AC5® Advanced Wound System...

ARTH : 0.1608 (-19.60%)
Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System

Strategic Alliance Positioned to Grow Sales Opportunities in Non-Government Hospital Channel...

ARTH : 0.1608 (-19.60%)
Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities

AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplication...

ARTH : 0.1608 (-19.60%)
Arch Therapeutics Announces Appointment of Guy Fish to the Board

Brings Broad Industry Experience in Strategy and Execution...

ARTH : 0.1608 (-19.60%)

Barchart Exclusives

This Dividend-Yielding Tech Stock Looks a ‘Compelling Buy’ for 2026 After 2 Years of Underperformance
Microsoft is set to underperform markets for the second consecutive year. Dan Ives of Wedbush, meanwhile, sees it as a “compelling” buy and predicts nearly 30% upside next year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar